127 related articles for article (PubMed ID: 16430025)
1. Synthesis and biological activity of picobenzide (3,5-dimethyl-N-(pyridin-4-ylmethyl)benzamide) analogues as potential antipsychotic agents.
Gradillas A; López B; Braña MF; Sancho I; Pérez-García C; Alguacil LF
Arzneimittelforschung; 2005; 55(12):725-9. PubMed ID: 16430025
[TBL] [Abstract][Full Text] [Related]
2. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Bolós J; Gubert S; Anglada L; Planas JM; Burgarolas C; Castelló JM; Sacristán A; Ortiz JA
J Med Chem; 1996 Jul; 39(15):2962-70. PubMed ID: 8709130
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and bioactivity of aripiprazole derivatives.
Ge HX; Wang LC; Jiang ZZ; Ni SL
Arzneimittelforschung; 2006; 56(10):673-7. PubMed ID: 17225561
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological investigations of new 6-oxo-1,2,3,4-tetrahydro-6H-pyrimido[2,1-b]quinazoline derivatives.
Korzycka L; Szadowska A; Pakulska W
Pharmazie; 1994 Nov; 49(11):815-9. PubMed ID: 7838867
[TBL] [Abstract][Full Text] [Related]
5. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Norman MH; Rigdon GC; Hall WR; Navas F
J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
8. Neuropharmacological profile of MD 790501, a new benzamide derivative.
Jalfre M; Bucher B; Dorme N; Mocquet G; Porsolt RD
Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):232-56. PubMed ID: 6139097
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
[TBL] [Abstract][Full Text] [Related]
10. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
11. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
12. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
Worms P
Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
[No Abstract] [Full Text] [Related]
13. Potential neuroleptic agents. 2. Synthesis and dopamine blocking activity of some new 2,6-dimethoxybenzamide derivatives.
Florvall L; Persson ML; Ogren SO
Acta Pharm Suec; 1983; 20(5):365-70. PubMed ID: 6141698
[No Abstract] [Full Text] [Related]
14. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
[No Abstract] [Full Text] [Related]
16. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fuxe K; Werge T; Gerlach J
Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of the pharmacological activity of N-(4-picolyl)-3,5-dimethylbenzamide (M-14012-4) and its N-oxide metabolite (M-3312-4). New pharmacological aspects].
Casais L; Colom A; Martín del Río MP; Vallejo M; Cuenca E
Arch Farmacol Toxicol; 1979 Dec; 5(3):159-64. PubMed ID: 44673
[No Abstract] [Full Text] [Related]
18. Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
Sauerberg P; Jeppesen L; Olesen PH; Rasmussen T; Swedberg MD; Sheardown MJ; Fink-Jensen A; Thomsen C; Thøgersen H; Rimvall K; Ward JS; Calligaro DO; DeLapp NW; Bymaster FP; Shannon HE
J Med Chem; 1998 Oct; 41(22):4378-84. PubMed ID: 9784113
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological properties of new antipsychotic agents: use of animal models.
Puech AJ; Rioux P; Poncelet M; Brochet D; Chermat R; Simon P
Neuropharmacology; 1981 Dec; 20(12B):1279-84. PubMed ID: 6119637
[No Abstract] [Full Text] [Related]
20. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
